China Medicine Corp. (CHME) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.21 means the share price is 0.21 times one year of earnings per share.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerChina Medicine Corp. (CHME) trades at $0.021. China Medicine Corporation specializes in the production and distribution of pharmaceutical products, including traditional Chinese medicine and medical devices. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for CHME: CHME does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
China Medicine Corp. (CHME) Healthcare & Pipeline Overview
China Medicine Corporation is a key player in China's healthcare distribution sector, focusing on prescription and over-the-counter drugs, traditional Chinese medicine, and medical devices, leveraging a robust sales network to cater to diverse medical needs.
What Is the Investment Thesis for CHME?
China Medicine Corporation's investment thesis is underpinned by its strong market presence in the growing Chinese healthcare sector, characterized by increasing demand for pharmaceutical products. With a P/E ratio of 0.21, the company is valued attractively compared to industry peers, indicating potential for price appreciation. The company's diverse product range, including traditional Chinese medicine and modern pharmaceuticals, positions it well to capitalize on the rising trend of integrative medicine. Additionally, the company’s gross margin of 29.3% reflects operational efficiency, while a profit margin of 2.7% suggests room for improvement in cost management. As healthcare spending in China continues to grow, driven by an aging population and rising health awareness, China Medicine Corporation is poised to benefit from these trends. Key growth catalysts include expanding its product offerings, enhancing distribution capabilities, and potential regulatory approvals for new drugs. However, investors may want to evaluate the inherent risks associated with the OTC market and the company's reliance on the domestic market.
Based on FMP financials and quantitative analysis
CHME Key Highlights
P/E ratio of 0.21 indicates a low valuation compared to industry standards.
- Gross margin of 29.3% demonstrates the company's operational efficiency.
- Profit margin of 2.7% reflects the company's profitability amidst competitive pressures.
- The company employs 281 individuals, contributing to its operational capacity.
- No dividend yield, indicating a focus on reinvestment rather than shareholder returns.
Who Are CHME's Competitors?
CHME is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| HCM HUTCHMED (China) Limited | $13.45 | -3.86% | $2.34B | 70 5-pillar |
| CGEN Compugen Ltd. | $1.88 | -4.08% | $178M | 69 5-pillar |
| NVS Novartis AG | $155.21 | -2.46% | $293B | 82 5-pillar |
| BMY Bristol-Myers Squibb Company | $58.34 | -2.05% | $119B | 85 5-pillar |
| SNY Sanofi | $47.12 | -0.86% | $113B | 87 5-pillar |
| ONC BeOne Medicines Ltd. | $403.60 | -2.34% | $46.1B | 96 5-pillar |
| DMRA Galecto, Inc. | $24.30 | +5.74% | $1.50B | 50 5-pillar |
| CGEM Cullinan Therapeutics, Inc. | $9.07 | +0.67% | $589M | 51 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CHME's Key Strengths?
Diverse product offerings addressing a wide range of health issues.
- Strong sales network facilitating effective distribution.
- Established brand presence in the Chinese healthcare market.
- Expertise in traditional Chinese medicine enhancing product appeal.
What Are CHME's Weaknesses?
Limited international market presence compared to global competitors.
- Dependence on the domestic market for revenue generation.
- Low profit margin indicating potential cost management challenges.
- Lack of dividend payments may deter income-focused investors.
What Could Drive CHME Stock Higher?
Potential regulatory approvals for new pharmaceutical products.
- Expansion of product offerings to meet growing consumer demand.
- Strengthening of distribution network to enhance market reach.
- Strategic partnerships aimed at product development and innovation.
- Increasing focus on traditional Chinese medicine in product development.
What Are the Key Risks for CHME?
Financial-distress signal — its Altman Z-Score of 1.44 sits in the distress zone (elevated bankruptcy risk).
- Regulatory challenges impacting product approvals and market entry.
- Intense competition from both domestic and international pharmaceutical companies.
- Economic fluctuations affecting consumer spending on healthcare products.
- Supply chain disruptions impacting product availability.
What Are the Growth Opportunities for CHME?
- Expansion of Product Offerings: China Medicine Corporation can enhance its market position by expanding its product offerings, particularly in high-demand therapeutic areas such as oncology and chronic disease management.
- Increasing Demand for Traditional Chinese Medicine: There is a growing trend towards traditional Chinese medicine (TCM) as consumers seek holistic and natural treatment options. The TCM market in China is expected to grow at a CAGR of 10% through 2025. China Medicine Corporation's existing portfolio aligns well with this trend, allowing the company to leverage its expertise in TCM to meet rising consumer demand.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with healthcare providers and research institutions can enhance China Medicine Corporation's product development capabilities and market reach. Collaborations could facilitate access to new technologies and innovative treatment options, positioning the company for long-term growth in the competitive healthcare landscape.
- Geographic Expansion: China Medicine Corporation has the potential to expand its distribution network beyond domestic markets. By exploring opportunities in emerging markets, the company can diversify its revenue streams and mitigate risks associated with reliance on the Chinese market. The Asia-Pacific pharmaceutical market is expected to grow significantly, providing a fertile ground for expansion.
- Regulatory Approvals for New Products: Securing regulatory approvals for new drugs and medical devices can serve as a major growth catalyst for China Medicine Corporation. The company can enhance its product portfolio and market competitiveness by navigating the regulatory landscape effectively, capitalizing on the increasing demand for innovative healthcare solutions.
What Are CHME's Competitive Advantages?
- Established distribution network providing extensive market reach.
- Diverse product portfolio catering to various medical needs.
- Expertise in traditional Chinese medicine, aligning with consumer preferences.
- Strong brand recognition within the Chinese healthcare market.
- Ability to navigate regulatory environments effectively.
What Does CHME Do?
Founded in 2005, China Medicine Corporation has established itself as a significant entity in the healthcare distribution industry in China. Originally known as Lounsberry Holdings III, Inc., the company rebranded in May 2006 to reflect its focus on the pharmaceutical sector. Based in Guangzhou, China, China Medicine Corporation produces and distributes a wide array of products, including prescription medications, over-the-counter drugs, traditional Chinese medicine, herbs, dietary supplements, and medical devices. The company’s offerings target various medical applications, such as oncology, high blood pressure, and detoxification of food and animal feeds. Their product range addresses numerous health issues, including heart conditions, respiratory infections, hepatitis, and menstrual disorders. With a dedicated sales network across China, the company effectively reaches its customer base, ensuring the availability of its diverse product portfolio. The firm employs 281 individuals, contributing to its operational capabilities and market outreach. As the demand for healthcare products continues to rise in China, China Medicine Corporation is well-positioned to leverage its established distribution channels and product offerings to capture growth opportunities in this expanding market.
What Products and Services Does CHME Offer?
- Produce and distribute prescription and over-the-counter drugs.
- Offer traditional Chinese medicine products and herbs.
- Provide dietary supplements and medical devices.
- Develop medical formulations for various therapeutic applications.
- Address health issues such as oncology, high blood pressure, and respiratory infections.
- Utilize a comprehensive sales network across China for product distribution.
How Does CHME Make Money?
- Generate revenue through the sale of pharmaceutical products and medical devices.
- Leverage a robust distribution network to reach a wide customer base in China.
- Focus on both prescription and over-the-counter medication markets.
- Capitalize on the growing demand for traditional Chinese medicine and dietary supplements.
- Engage in strategic partnerships to enhance product offerings and market presence.
What Industry Does CHME Operate In?
The healthcare distribution industry in China is experiencing significant growth, driven by increasing healthcare expenditures and a rising demand for pharmaceutical products. The market is expected to expand as the Chinese government continues to invest in healthcare infrastructure and improve access to medical services. China Medicine Corporation operates within a competitive landscape that includes both domestic and international players. As the industry adapts to evolving consumer preferences, particularly towards traditional and integrative medicine, companies like China Medicine Corporation are strategically positioned to capture market share.
Who Are CHME's Key Customers?
- Healthcare providers including hospitals and clinics.
- Pharmacies and retail outlets across China.
- Consumers seeking over-the-counter medications and supplements.
- Patients requiring prescription medications for chronic conditions.
- Distributors and wholesalers in the pharmaceutical sector.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Financial Health
China Medicine Corp.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.44 places it in the distress zone, a signal of elevated financial risk.
Company Profile
China Medicine Corp. operates in the Healthcare sector. It is headquartered in Guangzhou, CN. The company is led by CEO Senshan Yang. CHME has traded publicly since 2006.
CHME Financials
Bull Case vs Bear Case
Bull Case
- Diverse product offerings addressing a wide range of health issues.
- Strong sales network facilitating effective distribution.
- Established brand presence in the Chinese healthcare market.
- Expertise in traditional Chinese medicine enhancing product appeal.
Bear Case
- Limited international market presence compared to global competitors.
- Dependence on the domestic market for revenue generation.
- Low profit margin indicating potential cost management challenges.
- Lack of dividend payments may deter income-focused investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
CHME Latest News
No recent news available for CHME.
CHME Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CHME.
Price Targets
Wall Street price target analysis for CHME.
CHME MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CHME; grades run from A+ (80-100) to F (below 30).
Leadership: Senshan Yang
CEO
Senshan Yang has been at the helm of China Medicine Corporation since its inception in 2005. With a background in pharmaceutical sciences, he has overseen the company's growth and strategic direction. Yang has extensive experience in the healthcare industry, having previously held various leadership roles in pharmaceutical companies. He holds a degree in pharmacy and has been instrumental in promoting the integration of traditional Chinese medicine with modern healthcare practices.
Track Record: Under Yang's leadership, China Medicine Corporation has successfully expanded its product portfolio and strengthened its distribution network across China. His strategic focus on traditional Chinese medicine has positioned the company to capitalize on emerging market trends, driving revenue growth and enhancing brand recognition.
CHME OTC Market Information
The OTC Other tier represents companies that trade on the over-the-counter market, typically with less stringent reporting requirements than those on major exchanges like NYSE or NASDAQ. This tier often includes smaller companies or those with limited financial disclosure, which may affect their visibility and investor confidence.
- OTC Tier: OTC Other
- Limited financial disclosures may pose risks regarding transparency and accountability.
- Lower liquidity in the OTC market can lead to price volatility and trading difficulties.
- Regulatory scrutiny and compliance risks associated with operating in the healthcare sector.
- Market perception issues due to the company's OTC classification.
- Verify the company's financial health and operational metrics.
- Assess the competitive landscape and market positioning.
- Review regulatory compliance and approval status for products.
- Investigate the company's distribution network and market reach.
- Evaluate management team's experience and track record.
- Established brand presence in the Chinese healthcare market.
- Diverse product portfolio addressing various health needs.
- Strong sales network facilitating effective distribution.
China Medicine Corp. Healthcare Stock: Key Questions Answered
Is CHME a good stock to buy?
Stock Expert AI does not rate CHME buy, sell or hold. China Medicine Corp. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CHME stock price today?
The last price recorded on this page for China Medicine Corp. (CHME) is $0.021, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about CHME stock?
As of the latest available data, there are no specific analyst ratings or price targets for CHME stock. However, the company’s low P/E ratio of 0.21 suggests that it may be undervalued compared to industry peers.
What are the key factors to evaluate for CHME?
Evaluate CHME on fundamentals, analyst consensus, and risk factors. P/E: 0.21x. P/E ratio of 0.21 indicates a low valuation compared to industry standards. Not financial advice.
How frequently does CHME data refresh on this page?
CHME's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CHME's recent stock price performance?
China Medicine Corp. (CHME) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product offerings addressing a wide range of health issues. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHME overvalued or undervalued right now?
China Medicine Corp. (CHME) trades at 0.21x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CHME before investing?
Before investing in China Medicine Corp. (CHME), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Limited financial disclosures may affect investor confidence and decision-making.